Drugs / Enhanced autologous PSMA-CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06228404 | Mar 2024 → May 2026 overdue | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Shanghai Changzheng Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enhanced autologous PSMA-CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06228404 ↗ |